# US 10,869,851 B1 · Targeting NUR77 for mitigating perinatal neuroinflammation > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,869,851 B1 - Document ID: US10869851B1 - Status: Granted - Kind: B1 - Application number: 15/916,353 - Filed: 2018-03-09 - Granted: 2020-12-22 - Earliest claimed: 2017-03-13 - Assignees: United States Government as represented by the Secretary of the Army - Applicants: The United States Government as represented by the Secretary of the Army - Inventors: Nicholas M. Ieronimakis; Andrew S. Thagard; Sarah M. Estrada; Peter Napolitano - Web page: https://patentgrep.com/patent/US10869851B1 ## CPC - A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate - A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 25/00: Drugs for disorders of the nervous system - A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Compositions and methods of inhibiting Nur77 in a subject for treatment of perinatal neuroinflammation, preterm labor, or preterm birth are provided. ## Claims ### Claim 1 A method of treating or inhibiting preterm birth of a fetus caused by abnormal expression of Nur77, which comprises administering to the fetus an effective amount of one or more Nur77 antagonists. ### Claim 2 A method of treating or inhibiting a disease or disorder selected from preterm labor, preterm birth, perinatal neuroinflammation, a perinatal neurological injury, a vascular injury, a neurodevelopmental disability, and cerebral palsy in a subject in need thereof, which comprises reducing or inhibiting expression of Nur77 or reducing or inhibiting Nur77 receptor signaling in the subject by administering to the subject an effective amount of one or more Nur77 antagonists, wherein the disease or disorder is caused by abnormal expression of Nur77. ### Claim 3 (depends on 2) The method of claim 2, wherein the one or more Nur77 antagonists is a nucleic acid molecule, a protein, a peptidomimetic, an antibody or an antigen-binding fragment (Fab) thereof, a ribozyme, or a small molecule. ### Claim 4 (depends on 2) The method of claim 2, wherein the one or more Nur77 antagonists is ethyl 2-(2,3,4-trimethoxy-6-octanoylphenyl)acetate (TMPA) or a pharmaceutically acceptable salt thereof. ### Claim 5 (depends on 2) The method of claim 2, wherein a therapeutically effective amount of the one or more Nur77 antagonists is administered to the subject. ### Claim 6 (depends on 2) The method of claim 2, wherein a prophylactically effective amount of the one or more Nur77 antagonists is administered to the subject. ### Claim 7 (depends on 2) The method of claim 2, wherein a dose of the one or more Nur77 antagonists is administered before, during, and/or after preterm birth of the subject. ### Claim 8 (depends on 2) The method of claim 2, wherein the subject is a fetus or a premature baby. ### Claim 9 (depends on 8) The method of claim 8, wherein the fetus is treated in utero by administering the one or more Nur77 antagonists to the mother. ### Claim 10 (depends on 1) The method according to claim 1, wherein the one or more Nur77 antagonists are administered to the subject in an amount of about 5 mg to about 500 mg per kg weight of the subject. ### Claim 11 (depends on 1) The method according to claim 1, wherein the one or more Nur77 antagonists are administered in the form of a pharmaceutical composition. ### Claim 12 (depends on 1) The method according to claim 1, which further comprises administering to the subject magnesium sulfate and/or betamethasone. ### Claim 13 (depends on 1) The method according to claim 1, which further comprises administering to the subject one or more supplementary agents. ### Claim 14 (depends on 13) The method according to claim 13, wherein the one or more supplementary agents is a corticosteroid, an immunosuppressant, an anti-inflammatory agent, an anti-ischemic agent, or a palliative agent. ### Claim 15 (depends on 1) The method of claim 1, wherein the one or more Nur77 antagonists is a nucleic acid molecule, a protein, a peptidomimetic, an antibody or an antigen-binding fragment (Fab) thereof, a ribozyme, or a small molecule. ### Claim 16 (depends on 1) The method of claim 1, wherein the one or more Nur77 antagonists is ethyl 2-(2,3,4-trimethoxy-6-octanoylphenyl)acetate (TMPA) or a pharmaceutically acceptable salt thereof. ### Claim 17 (depends on 1) The method of claim 1, wherein the fetus is treated in utero by administering the one or more Nur77 antagonists to the mother. ### Claim 18 (depends on 2) The method according to claim 2, wherein the one or more Nur77 antagonists are administered to the subject in an amount of about 5 mg to about 500 mg per kg weight of the subject. ### Claim 19 (depends on 2) The method according to claim 2, which further comprises administering to the subject magnesium sulfate and/or betamethasone. ### Claim 20 (depends on 2) The method according to claim 2, which further comprises administering to the subject one or more supplementary agents. ### Claim 21 (depends on 20) The method according to claim 20, wherein the one or more supplementary agents is a corticosteroid, an immunosuppressant, an anti-inflammatory agent, an anti-ischemic agent, or a palliative agent.